FIZE Medical

Executive Summary

FIZE Medical is an Israeli medtech company commercializing the FIZE kUO platform, an AI-powered, real-time urine output monitoring system for critically ill patients. The platform continuously measures kidney urine output, integrates with electronic medical records (EMR), and provides early alerts for acute kidney injury and fluid imbalances. Founded in 2020 and based in Caesarea, the company targets hospitals and intensive care units worldwide. With a commercial-stage product and a focus on improving outcomes in critical care and nephrology, FIZE Medical addresses a significant unmet need in fluid management. The company's solution aims to reduce the incidence of acute kidney injury and improve patient outcomes by enabling proactive clinical interventions. As of 2026, the company is privately held and has not disclosed funding or valuation, but its market traction and technology position it for growth in the digital health and critical care monitoring space.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Next-Generation Platform70% success
• Q2 2026Publication of Clinical Validation Study in Major Journal60% success
• Q4 2026Strategic Partnership with Major Hospital Network50% success